Beovu Market Report 2026

Beovu Market Overview

• The Beovu market growth in the historic period has been driven by increasing amd prevalence, diabetic eye disease growth • Market expansion is supported by aging global population, rising diabetes incidence • Growth Driver: Impact Of Rising Retinal Disease Incidence On The Beovu Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Beovu Market?

Beovu (brolucizumab) is a prescription medication used to treat specific eye conditions, such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). This monoclonal antibody works by blocking vascular endothelial growth factor (VEGF-A), a protein involved in the formation of abnormal blood vessels in the eye, which can lead to vision issues. The main types of beovu market are macular degeneration, diabetic retinopathy, and other types. Macular degeneration is an eye condition that affects the central part of the retina, called the macula, leading to vision loss. It is one of the most common causes of impaired vision in older adults and can progress to a severe stage, particularly wet age-related macular degeneration (wet AMD), which may require treatments such as Beovu. The various dosage forms include gels, eye solutions, capsules and tablets, eye drops, and ointments. These are distributed through various channels such as hospital pharmacy, online pharmacy, and retail pharmacy and used by various end users such as adult, and geriatric.

What Is The Beovu Market Growth Forecast?

The growth in the forecast period can be attributed to aging global population, rising diabetes incidence, demand for durable therapies, improved retinal screening programs, outpatient treatment growth. Major trends in the forecast period include rising use of anti vegf therapies, preference for longer dosing intervals, growth of retinal disease treatment demand, expansion of outpatient ophthalmic care, focus on vision preservation in aging populations.

Global Beovu Market Segmentation

1) By Type: Macular Degeneration, Diabetic Retinopathy, Other Types 2) By Dosage Form: Gels, Eye Solutions, Capsules And Tablets, Eye Drops, Ointments 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy 4) By End User: Adult, Geriatric

What Are The Drivers Of The Beovu Market?

The rising incidence of retinal diseases is expected to boost the growth of the beovu market going forward. Retinal diseases refer to a group of conditions that affect the retina, the light-sensitive tissue at the back of the eye, which includes disorders such as age-related macular degeneration (AMD), diabetic retinopathy, retinal detachment, and macular edema, often leading to vision impairment. The rise in retinal diseases is due to ageing populations, increasing diabetes cases, prolonged screen exposure, and genetic factors, leading to higher rates of vision impairment and blindness. Beovu treats retinal diseases by inhibiting VEGF, which reduces fluid leakage and swelling in the retina, helping to improve vision, prevent disease progression, and enhance patient outcomes for conditions such as wet AMD and diabetic macular edema. For instance, according to the National Eye Institute, a US-based government agency, 2.7 million Americans are living with glaucoma, and this number is projected to increase to 4.3 million by 2030. Additionally, 7.7 million Americans are affected by diabetic retinopathy, and this figure is expected to rise to 11.3 million by 2030. Therefore, the rising incidence of retinal diseases is driving growth in the beovu industry. The growing geriatric population is expected to propel the growth of the beovu market going forward. The geriatric population refers to individuals who are generally 65 years of age or older, and it encompasses the elderly who may experience various health, social, and functional changes due to aging. The growing geriatric population is attributed to factors such as advancements in healthcare, improved living conditions, better nutrition, and increased life expectancy. Beovu (brolucizumab) aids the geriatric population by managing age-related macular degeneration (AMD), a common cause of vision impairment in older adults, by decreasing retinal fluid accumulation and helping to stabilize or enhance vision. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is projected to rise to 22.1 million by 2072, accounting for 27% of the population. Therefore, the growing geriatric population will drive the growth in the beovu industry. The rising healthcare expenditure is expected to propel the growth of the beovu market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Rising healthcare expenditure enhances Beovu adoption by expanding access to advanced ophthalmic treatments, making it more attainable for patients with retinal disorders such as age-related macular degeneration. It supports improved clinical outcomes by enabling investment in innovative biologic therapies, strengthening vision care and overall patient well-being. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the beovu market

Key Players In The Global Beovu Market

Major companies operating in the beovu market are Novartis AG

Regional Insights

North America was the largest region in the beovu market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Beovu Market?

The beovu market consists of sales of beovu vials, pre-filled syringes, multi-dose vials, and single-use injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Beovu Market Report 2026?

The beovu market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the beovu industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.